Abstract:Angiotensin converting enzyme (ACE) inhibitors have offered new perspectives in the treatment of hypertension. The development of new ACE inhibitors such as ramipril provides an opportunity to improve the knowledge on this class of drug, and to optimize the benefit/risk ratio for the patient. Ramipril was selected among several analogs because of its unique physicochemical properties. It is a nonsulfhydryl ACE inhibitor, and after oral absorption it is transformed in the liver into its active metabolite ramiprilat. which is at least 23 times more lipophilic than enalaprilat. Furthermore, the in vitro affinity of ramiprilat for the enzyme is 7 times higher than for enalaprilat and 47 times higher than for captopril. The ramiprilat-ACE complex is therefore very stable and dissociates 6 times more slowly than the enalaprilat-ACE complex and 22 times more slowly than the captopril-ACE complex. Ramipril possesses a favorable pharmacokinetic profile as a consequence of its physicochemical properties: its high potency allows the use of very low doses, and the slow dissociation of the ramipril-ACE complex explains the long duration of its action, permitting a once-daily treatment. Dose-finding studies have confirmed that very low doses of ramipril–2.5 mg once a day–can be used as a first-step treatment of hypertension. This dose can be increased up to 5 mg, and if necessary a low dose of a diuretic can be added. Using this therapeutic scheme, ramipril normalized blood pressure, insuring that each patient receives the smallest effective dose. Inhibition of the tissue renin-angiotensin system by ramipril has been described in recent studies on animal models. The effects of ramipril on the target organs of hypertension have been compared to those of other ACE inhibitors: possibly due to its lipophilicity, ramipril inhibits the renin-angiotensin system in the heart, kidney, and vascular wall, and the local production of angiotensin II is decreased by the treatment. In clinical trials, a rapid regression of cardiac hypertrophy was shown in hypertensive patients. Furthermore, ramipril is able to exert an antivaso-constrictor effect during infusion of angiotensin I in the brachial artery of healthy volunteers. Ramipril can also decrease blood pressure in binephrectomized hypertensive patients despite the absence of renin secreted by the kidney. These results provide indirect evidence that ramipril may exert an inhibitory effect on tissue renin-angiotensin systems in humans.

Protective Effect of Emodin on WI-38 Cell Toxicity Induced by Cisplatin

Protective effect of schisandrin B against HK-2 apoptosis induced by Cisplatin

Ameliorative Effect of Daidzein on Cisplatin-Induced Nephrotoxicity in Mice via Modulation of Inflammation, Oxidative Stress, and Cell Death.

Mitochondrial Modulation by Epigallocatechin 3-Gallate Ameliorates Cisplatin Induced Renal Injury Through Decreasing Oxidative/nitrative Stress, Inflammation and NF-kB in Mice.

Inhibitory Effect of Cisplatin on Proteasome

Protective effect of urolithin a on cisplatin-induced nephrotoxicity in mice via modulation of inflammation and oxidative stress

Preventive Effect of Meglumine on Rat's Nephrotoxicity Induced by Cisplatin and Discussion on Its Mechanism

THE PROTECTIVE EFFECT OF MELATONIN ON AUDITORY CORTEX TOXICITY INDUCED BY CIS-PLATINUM

Protective Effect Of Metalloporphyrins Against Cisplatin-Induced Kidney Injury In Mice

Inhibitory Effect of Platycodin D on Human Colonic Cancer SW620 Cell Proliferation

Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells

Mechanism of regulating the resistance of prostate cancer PC-3 cells to cisplatin through enhancing cell gap junctions by evodiamine

Platycodin D suppresses cisplatin‐induced cytotoxicity by suppressing ROS‐mediated oxidative damage, apoptosis, and inflammation in HEK‐293 cells

Based on network pharmacology and molecular docking to explore the protective effect of Epimedii Folium extract on cisplatin-induced intestinal injury in mice

The Renin‐Angiotensin System and Ramipril, A New Converting Enzyme Inhibitor

Bisdemethoxycurcumin Attenuates Cisplatin-Induced Renal Injury Through Anti-Apoptosis, Anti-Oxidant and Anti-Inflammatory

Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats

Indole-3-carboxaldehyde alleviates cisplatin-induced acute kidney injury in mice by improving mitochondrial dysfunction via PKA activation

Establishment of Cisplatin-Resistant Human Endometrial Cancer Cell Line and the Study of Its Resistant Mechanisms

Huangqi-Danshen decoction protects against cisplatin-induced acute kidney injury in mice

Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression